# Beneficial biological effects and the underlying mechanisms of molecular hydrogen - comprehensive review of 321 original articles -

**Authors:** Masatoshi Ichihara, Sayaka Sobue, Mikako Ito, Masafumi Ito, Masaaki Hirayama, Kinji Ohno

PMC · DOI: 10.1186/s13618-015-0035-1 · 2015-10-19

## TL;DR

Molecular hydrogen shows therapeutic effects in many diseases by reducing oxidative stress and inflammation, though its exact mechanisms are still being studied.

## Contribution

A comprehensive review of 321 studies reveals hydrogen's broad biological effects and potential molecular mechanisms.

## Key findings

- Molecular hydrogen reduces oxidative stress and inflammation in various disease models.
- Hydrogen's effects are observed in 31 disease categories across multiple organs.
- Hydrogen modulates activities of molecules like Lyn, ERK, and NF-κB p65.

## Abstract

Therapeutic effects of molecular hydrogen for a wide range of disease models and human diseases have been investigated since 2007. A total of 321 original articles have been published from 2007 to June 2015. Most studies have been conducted in Japan, China, and the USA. About three-quarters of the articles show the effects in mice and rats. The number of clinical trials is increasing every year. In most diseases, the effect of hydrogen has been reported with hydrogen water or hydrogen gas, which was followed by confirmation of the effect with hydrogen-rich saline. Hydrogen water is mostly given ad libitum. Hydrogen gas of less than 4 % is given by inhalation. The effects have been reported in essentially all organs covering 31 disease categories that can be subdivided into 166 disease models, human diseases, treatment-associated pathologies, and pathophysiological conditions of plants with a predominance of oxidative stress-mediated diseases and inflammatory diseases. Specific extinctions of hydroxyl radical and peroxynitrite were initially presented, but the radical-scavenging effect of hydrogen cannot be held solely accountable for its drastic effects. We and others have shown that the effects can be mediated by modulating activities and expressions of various molecules such as Lyn, ERK, p38, JNK, ASK1, Akt, GTP-Rac1, iNOS, Nox1, NF-κB p65, IκBα, STAT3, NFATc1, c-Fos, and ghrelin. Master regulator(s) that drive these modifications, however, remain to be elucidated and are currently being extensively investigated.

## Linked entities

- **Genes:** LYN (LYN proto-oncogene, Src family tyrosine kinase) [NCBI Gene 4067], EPHB2 (EPH receptor B2) [NCBI Gene 2048], CRK (CRK proto-oncogene, adaptor protein) [NCBI Gene 1398], MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599], MAP3K5 (mitogen-activated protein kinase kinase kinase 5) [NCBI Gene 4217], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843], NOX1 (NADPH oxidase 1) [NCBI Gene 27035], NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774], NFATC1 (nuclear factor of activated T cells 1) [NCBI Gene 4772], FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353]
- **Chemicals:** hydrogen (PubChem CID 783), hydroxyl radical (PubChem CID 157350), peroxynitrite (PubChem CID 104806)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Nfe2l2 (nuclear factor, erythroid derived 2, like 2) [NCBI Gene 18024] {aka Nrf2}, GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, MAP3K5 (mitogen-activated protein kinase kinase kinase 5) [NCBI Gene 4217] {aka ASK1, MAPKKK5, MEKK5}, MIR21 (microRNA 21) [NCBI Gene 406991] {aka MIRN21, hsa-mir-21, miR-21, miRNA21}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, Ghrl (ghrelin and obestatin prepropeptide) [NCBI Gene 59301], NFATC1 (nuclear factor of activated T cells 1) [NCBI Gene 4772] {aka NF-ATC, NF-ATc1.2, NFAT2, NFATc}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, G6PC1 (glucose-6-phosphatase catalytic subunit 1) [NCBI Gene 2538] {aka G6PC, G6PT, G6Pase, GSD1, GSD1a}, WEE1 (WEE1 G2 checkpoint kinase) [NCBI Gene 7465] {aka WEE1A, WEE1hu}, EGR1 (early growth response 1) [NCBI Gene 1958] {aka AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268}, BCL6 (BCL6 transcription repressor) [NCBI Gene 604] {aka BCL5, BCL6A, LAZ3, ZBTB27, ZNF51}, Hmox1 (heme oxygenase 1) [NCBI Gene 15368] {aka D8Wsu38e, HO-1, HO1, Hemox, Hmox, Hsp32}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, NOX1 (NADPH oxidase 1) [NCBI Gene 27035] {aka GP91-2, MOX1, NOH-1, NOH-1L, NOH1}, LYN (LYN proto-oncogene, Src family tyrosine kinase) [NCBI Gene 4067] {aka JTK8, SAIDV, p53Lyn, p56Lyn}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, APOM (apolipoprotein M) [NCBI Gene 55937] {aka G3a, HSPC336, NG20, apo-M}, Keap1 (kelch-like ECH-associated protein 1) [NCBI Gene 50868] {aka INRF2, mKIAA0132}, Ghsr (growth hormone secretagogue receptor) [NCBI Gene 84022], MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, ISYNA1 (inositol-3-phosphate synthase 1) [NCBI Gene 51477] {aka INO1, INOS, IPS, IPS 1, IPS-1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta) [NCBI Gene 3551] {aka IKK-2, IKK-beta, IKK2, IKKB, IMD15, IMD15A}, Lyn (Lyn proto-oncogene, Src family tyrosine kinase) [NCBI Gene 17096] {aka Hck-2, p53Lyn, p56Lyn}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, PDCD4 (programmed cell death 4) [NCBI Gene 27250] {aka H731}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}
- **Diseases:** cerebral infarction (MESH:D002544), Brain    Cerebrovascular diseases (MESH:D002561), Rheumatoid arthritis (MESH:D001172), polymyositis (MESH:D017285), metabolic acidosis (MESH:D000138), loss (MESH:D016388), Parkinson disease (MESH:D010300), Post cardiac arrest syndrome (MESH:D000080942), metabolic diseases (MESH:D008659), Asthma (MESH:D001249), hyperoxic lung injury (MESH:D055370), edema (MESH:D004487), Subarachnoid hemorrhage (MESH:D013345), Interstitial (MESH:D065167), tongue carcinoma (MESH:D014062), tumor (MESH:D009369), Muscle (MESH:D019042), neurotoxicity (MESH:D020258), Chronic obstructive pulmonary disease (MESH:D029424), Hepatitis and liver cirrhosis (MESH:D008103), squamous cell carcinoma (MESH:D002294), Chronic renal failure (MESH:D007676), cerebral hypoxia (MESH:D002534), blood alkalinity (MESH:D006402), Multiple system atrophy (MESH:D019578), dermatitis (MESH:D003872), immune dysfunction (MESH:D007154), mitochondrial myopathies (MESH:D017240), thymic lymphoma     Tumor (MESH:D013953), Diabetes mellitus type II (MESH:D003924), leukemia (MESH:D007938), skin injury (MESH:D000069836), Cerebral ischemia (MESH:D002545), Inflammation (MESH:D007249), nitrogen narcosis (MESH:D007222), Retinal artery occlusion (MESH:D015356), dermatomyositis (MESH:D003882), reperfusion injuries (MESH:D015427), Diabetic retinopathy (MESH:D003930), cartilage toxicity (MESH:D002357), heart failure (MESH:D006333), dementia (MESH:D003704), Chronic hepatitis B (MESH:D019694), impaired fasting glycaemia (MESH:D007003), ototoxicity (MESH:D006311), Retinal I/R injury (MESH:D012173), schistosomiasis (MESH:D012552), /R injury (MESH:C580424), Preeclampsia (MESH:D011225), Spinal cord I/R injury (MESH:D013119), urinary stone (MESH:D014545), Hyperlipidemia (MESH:D006949), cystitis (MESH:D003556), brain damage (MESH:D001925), stroke (MESH:D020521), retinopathy (MESH:D058437), Cardiac damage (MESH:D006331), Perinatal (MESH:D066087), ischemia (MESH:D007511), Neuropathic pain     Hyperalgesia (MESH:D009437)
- **Species:** Homo sapiens (human, species) [taxon 9606], Cricetus cricetus (black-bellied hamster, species) [taxon 10034], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4610055/full.md

---
Source: https://tomesphere.com/paper/PMC4610055